Abstract
This focused chapter serves as a short survey of glycan microarrays that are available with sialylated glycans, including both defined and shotgun arrays, their generation, and their utility in studying differential binding interactions to sialylated compounds, highlighting N-glycolyl (Gc) modified sialylated compounds. A brief discussion of binding interactions by lectins, antibodies, and viruses, and their relevance that have been observed with sialylated glycan microarrays is presented, as well as a discussion of cross-comparisons of array platforms and efforts to centralize and standardize the glycan microarray data.
Introduction to Glycan Microarrays as a Tool to Study Glycan Binding Interactions
Glycan microarray technology has enabled unprecedented examination of the binding interactions between glycan binding proteins (GBPs) and host carbohydrates, as discoveries are continually being made about the significance and utility of glycans in various biological interactions. The microarray tools can be broadly grouped into (a) defined arrays with known glycan structures, and (b) undefined arrays with unknown structures, which would include arrays derived from natural source material and chemical or enzymatically modified materials that may not be fully characterized. Many of the available glycan microarray platforms contain a variety of sialylated glycans, including the N-acetyl (Ac) and N-glycolyl (Gc) forms. Sialylated glycans have been especially recognized for their significant biological roles, thus creating particular interest in sialylated glycan microarrays.
Diversity of Glycan Microarray Platforms
Synthesis of Sialosides
The sialosides and sialic acid derivatives that populate various microarrays are generated from different sources. Chemo-enzymatic and semi-synthetic approaches have been taken for many compounds, when root glycan structures were available for further modification by sialyltransferases or chemical approaches (Blixt et al., ). The most extensive variety of sialosides, containing Ac and Gc forms as well as other modifications, for use on microarrays and in other applications has been derived by the laboratory of Xi Chen (Yu et al., , ,, ; Chokhawala et al., ; Linman et al., ; Khedri et al., ; Li et al., ). This work uses novel one-pot synthesis and combinatorial methods, and is the subject of another review in this issue (Chen et al., ). The diversity and biological applications of large libraries of natural and non-natural sialosides and their chemical approaches were well described in previous reviews (Deng et al., ; Liang et al., ).
Consortium for Functional Glycomics
One of the most successful and widely used glycan microarrays has been created by the Consortium for Functional Glycomics (CFG, www.functionalglycomics.org). It is a defined, synthetic glycan microarray and is the largest publicly available glycan microarray with ~600 printed glycans on the latest version, of which approximately 20 percent are sialylated (Table 1; Blixt et al., ). There are 14 compounds that contain a Neu5Gc, in either an O-glycan backbone or in a ganglioside structure, as well as the monosaccharide. The CFG array has been extensively utilized to identify and study the interactions of many GBPs including galectins, C-type lectins, and siglecs; immune molecules such as anti-glycan and anti-microbial antibodies and receptors; pathogenic toxins and pathogens such as HIV and parainfluenza virus hemagglutinin-neuraminidase glycoprotein (http://www.functionalglycomics.org/static/consortium/Library.shtml) (Stowell et al., ; Hickey et al., ; Alymova et al., , ; Blackler et al., ; Hussein et al., ; Jobling, ; Jones et al., ; Malik et al., ; Petrova et al., ; Schroeder et al., ; Vainauskas et al., ; Collins et al., ; Noach et al., ). The CFG glycan microarray was instrumental in identifying the anti-carbohydrate antibodies found in human intravenous immunoglobulin (IVIG) (Schneider et al., ) and helping to elucidate the specificity for Neu5Gc of an E. coli derived subtilase toxin (Day et al., ).
Table 1
| Sialylated glycans on CFG array | |
|---|---|
| Neu5Aca-Sp8 | Neu5Aca2-6(Galb1-3)GlcNAcb1-4Galb1-4Glcb-Sp10 |
| Neu5Aca-Sp11 | Neu5Aca2-6Galb1-4GlcNAcb1-2Mana1-3Manb1-4GlcNAcb1-4GlcNAc-Sp12 |
| Neu5Acb-Sp8 | Neu5Aca2-6Galb1-4GlcNAcb1-2Mana1-6(Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp12 |
| Neu5Aca2-3(6S)Galb1-4GlcNAcb-Sp8 | Neu5Aca2-6Galb1-4GlcNAcb1-2Mana1-6(GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp12 |
| Neu5Aca2-3Galb-Sp8 | Neu5Aca2-6Galb1-4GlcNAcb1-2Mana1-6(GlcNAcb1-4)(Neu5Aca2-6Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp21 |
| Neu5Aca2-3Galb1-3(6S)GalNAca-Sp8 | Neu5Aca2-6Galb1-4GlcNAcb1-2Mana1-6(Mana1-3)Manb1-4GlcNAcb1-4GlcNAc-Sp12 |
| Neu5Aca2-3Galb1-3(6S)GlcNAc-Sp8 | Neu5Aca2-6Galb1-4GlcNAcb1-2Mana1-6(Neu5Aca2-6Galb1-4GlcNAcb1-2Man-a1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp21 |
| Neu5Aca2-3Galb1-3(Fuca1-4)GlcNAcb-Sp8 | Neu5Aca2-6Galb1-4GlcNAcb1-2Mana1-6(Neu5Aca2-6Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4(Fuca1-6)GlcNAcb-Sp24 |
| Neu5Aca2-3Galb1-3(Fuca1-4)GlcNAcb1-3Galb1-3(Fuca1-4)GlcNAcb-Sp0 | Neu5Aca2-6Galb1-4GlcNAcb1-2Mana1-6(Neu5Aca2-6Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp12 |
| Neu5Aca2-3Galb1-3(Fuca1-4)GlcNAcb1-3Galb1-4(Fuca1-3)GlcNAcb-Sp0 | Neu5Aca2-6Galb1-4GlcNAcb1-2Mana1-6(Neu5Aca2-6Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp24 |
| Neu5Aca2-3Galb1-3GalNAca-Sp14 | Neu5Aca2-6Galb1-4GlcNAcb1-2Mana1-6Manb1-4GlcNAcb1-4GlcNAc-Sp12 |
| Neu5Aca2-3Galb1-3GalNAca-Sp8 | Neu5Aca2-6Galb1-4GlcNAcb1-3Galb1-3GlcNAcb-Sp0 |
| Neu5Aca2-3Galb1-3GalNAcb1-3Gala1-4Galb1-4Glcb-Sp0 | Neu5Aca2-6Galb1-4GlcNAcb1-3Galb1-4(Fuca1-3)GlcNAcb1-3Galb1-4(Fuca1-3)GlcNAcb-Sp0 |
| Neu5Aca2-3Galb1-3GalNAcb1-4(Neu5Aca2-3)Galb1-4Glcb-Sp0 | Neu5Aca2-6Galb1-4GlcNAcb1-3Galb1-4GlcNAcb-Sp0 |
| Neu5Aca2-3Galb1-3GalNAcb1-4Galb1-4Glcb-Sp0 | Neu5Aca2-6Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-6(Neu5Aca2-6Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp12 |
| Neu5Aca2-3Galb1-3GlcNAcb-Sp0 | Neu5Aca2-6Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb-Sp0 |
| Neu5Aca2-3Galb1-3GlcNAcb1-2Mana-Sp0 | Neu5Aca2-6Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-6(Neu5Aca2-6Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp12 |
| Neu5Aca2-3Galb1-3GlcNAcb1-2Mana1-6(GlcNAcb1-4)(Neu5Aca2-3Galb1-3GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAc-Sp21 | Neu5Aca2-6Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3GalNAca-Sp14 |
| Neu5Aca2-3Galb1-3GlcNAcb1-2Mana1-6(Neu5Aca2-3Galb1-3GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAc-Sp19 | Neu5Aca2-6Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-6(Galb1-3)GalNAca-Sp14 |
| Neu5Aca2-3Galb1-3GlcNAcb1-3Galb1-3GlcNAcb-Sp0 | Neu5Aca2-6Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-6(Neu5Aca2-6Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3)GalNAca-Sp14 |
| Neu5Aca2-3Galb1-3GlcNAcb1-3Galb1-4GlcNAcb-Sp0 | Neu5Aca2-6Galb1-4GlcNAcb1-3GalNAc-Sp14 |
| Neu5Aca2-3Galb1-3GlcNAcb1-3GalNAca-Sp14 | Neu5Aca2-6Galb1-4GlcNAcb1-4Mana1-6(GlcNAcb1-4)(Neu5Aca2-6Galb1-4GlcNAcb1-4(Neu5Aca2-6Galb1-4GlcNAcb1-2)Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp21 |
| Neu5Aca2-3Galb1-3GlcNAcb1-6GalNAca-Sp14 | Neu5Aca2-6Galb1-4GlcNAcb1-6(Fuca1-2Galb1-3GlcNAcb1-3)Galb1-4Glc-Sp21 |
| Neu5Aca2-3Galb1-4(6S)GlcNAcb-Sp8 | Neu5Aca2-6Galb1-4GlcNAcb1-6(Fuca1-2Galb1-4(Fuca1-3)GlcNAcb1-3)Galb1-4Glc-Sp21 |
| Neu5Aca2-3Galb1-4(Fuca1-3)(6S)GlcNAcb-Sp8 | Neu5Aca2-6Galb1-4GlcNAcb1-6(Galb1-3)GalNAca-Sp14 |
| Neu5Aca2-3Galb1-4(Fuca1-3)GlcNAcb-Sp0 | Neu5Aca2-6Galb1-4GlcNAcb1-6(Galb1-3GlcNAcb1-3)Galb1-4Glcb-Sp21 |
| Neu5Aca2-3Galb1-4(Fuca1-3)GlcNAcb-Sp8 | Neu5Aca2-6Galb1-4GlcNAcb1-6(Neu5Aca2-6Galb1-4GlcNAcb1-2)Mana1-6(GlcNAcb1-4)(Neu5Aca2-6Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp21 |
| Neu5Aca2-3Galb1-4(Fuca1-3)GlcNAcb1-2Mana-Sp0 | Neu5Aca2-6Galb1-4GlcNAcb1-6(Neu5Aca2-6Galb1-4GlcNAcb1-2)Mana1-6(GlcNAcb1-4)(Neu5Aca2-6Galb1-4GlcNAcb1-4(Neu5Aca2-6Galb1-4GlcNAcb1-2)Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp21 |
| Neu5Aca2-3Galb1-4(Fuca1-3)GlcNAcb1-3Galb-Sp8 | Neu5Aca2-6Galb1-4GlcNAcb1-6GalNAca-Sp14 |
| Neu5Aca2-3Galb1-4(Fuca1-3)GlcNAcb1-3Galb1-4(Fuca1-3)GlcNAcb1-3Galb1-4(Fuca1-3)GlcNAcb-Sp0 | Neu5Aca2-6GalNAca-Sp8 |
| Neu5Aca2-3Galb1-4(Fuca1-3)GlcNAcb1-3Galb1-4GlcNAcb-Sp8 | Neu5Aca2-6GalNAcb1-4(6S)GlcNAcb-Sp8 |
| Neu5Aca2-3Galb1-4(Fuca1-3)GlcNAcb1-3GalNAca-Sp14 | Neu5Aca2-6GalNAcb1-4GlcNAcb-Sp0 |
| Neu5Aca2-3Galb1-4(Fuca1-3)GlcNAcb1-6(Galb1-3)GalNAca-Sp14 | Neu5Aca2-6GlcNAcb1-4GlcNAc-Sp21 |
| Neu5Aca2-3Galb1-4(Fuca1-3)GlcNAcb1-6(Neu5Aca2-3Galb1-3)GalNAc-Sp14 | Neu5Aca2-6GlcNAcb1-4GlcNAcb1-4GlcNAc-Sp21 |
| Neu5Aca2-3Galb1-4(Neu5Aca2-3Galb1-3)GlcNAcb-Sp8 | Galb1-4GlcNAcb1-6(Neu5Aca2-6Galb1-3GlcNAcb1-3)Galb1-4Glc-Sp21 |
| Neu5Aca2-3Galb1-4Glcb-Sp0 | Galb1-4GlcNAcb1-2Mana1-6(Neu5Aca2-6Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp12 |
| Neu5Aca2-3Galb1-4Glcb-Sp8 | Mana1-6(Neu5Aca2-6Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAc-Sp12 |
| Neu5Aca2-3Galb1-4GlcNAcb-Sp0 | Neu5Acb2-6GalNAca-Sp8 |
| Neu5Aca2-3Galb1-4GlcNAcb-Sp8 | Neu5Acb2-6(Galb1-3)GalNAca-Sp8 |
| Neu5Aca2-3Galb1-4GlcNAcb1-2Mana-Sp0 | Neu5Acb2-6Galb1-4GlcNAcb-Sp8 |
| Neu5Aca2-3Galb1-4GlcNAcb1-2Mana1-6(GlcNAcb1-4)(Neu5Aca2-3Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp21 | Neu5Aca2-8Neu5Aca-Sp8 |
| Neu5Aca2-3Galb1-4GlcNAcb1-2Mana1-6(Neu5Aca2-3Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4(Fuca1-6)GlcNAcb-Sp24 | Neu5Aca2-8Neu5Acb-Sp17 |
| Neu5Aca2-3Galb1-4GlcNAcb1-2Mana1-6(Neu5Aca2-3Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp12 | Neu5Aca2-8Neu5Aca2-8Neu5Aca-Sp8 |
| Neu5Aca2-3Galb1-4GlcNAcb1-3Galb-Sp8 | Neu5Aca2-8Neu5Aca2-8Neu5Acb-Sp8 |
| Neu5Aca2-3Galb1-4GlcNAcb1-3Galb1-3GlcNAcb-Sp0 | Neu5Aca2-8Neu5Aca2-3Galb1-4Glcb-Sp0 |
| Neu5Aca2-3Galb1-4GlcNAcb1-3Galb1-4(Fuca1-3)GlcNAcb-Sp0 | Neu5Aca2-8Neu5Gca2-3Galb1-4GlcNAc-Sp0 |
| Neu5Aca2-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb-Sp0 | Neu5Aca2-8Neu5Aca2-3Galb1-4GlcNAc-Sp0 |
| Neu5Aca2-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-6(Neu5Aca2-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp12 | Neu5Aca2-8Neu5Aca2-8Neu5Aca2-3Galb1-4Glcb-Sp0 |
| Neu5Aca2-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb-Sp0 | Neu5Aca2-8Neu5Aca2-3Galb1-3GalNAcb1-4(Neu5Aca2-3)Galb1-4Glc-Sp21 |
| Neu5Aca2-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-6(Neu5Aca2-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp12 | Neu5Aca2-8Neu5Aca2-3Galb1-3GalNAcb1-4(Neu5Aca2-8Neu5Aca2-3)Galb1-4Glcb-Sp0 |
| Neu5Aca2-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3GalNAca-Sp14 | GalNAcb1-4(Neu5Aca2-8Neu5Aca2-3)Galb1-4Glcb-Sp0 |
| Neu5Aca2-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-6(Galb1-3)GalNAca-Sp14 | GalNAcb1-4(Neu5Aca2-8Neu5Aca2-8Neu5Aca2-8Neu5Aca2-3)Galb1-4Glcb-Sp0 |
| Neu5Aca2-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-6(Neu5Aca2-3Galb1-4GlcNAcb1-3Galb1-4GlcNAcb1-3)GalNAca-Sp14 | GalNAcb1-4(Neu5Aca2-8Neu5Aca2-8Neu5Aca2-3)Galb1-4Glcb-Sp0 |
| Neu5Aca2-3Galb1-4GlcNAcb1-3GalNAc-Sp14 | Galb1-3GalNAcb1-4(Neu5Aca2-8Neu5Aca2-8Neu5Aca2-3)Galb1-4Glcb-Sp21 |
| Neu5Aca2-3Galb1-4GlcNAcb1-4Mana1-6(GlcNAcb1-4)(Neu5Aca2-3Galb1-4GlcNAcb1-4(Neu5Aca2-3Galb1-4GlcNAcb1-2)Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp21 | Neu5Gca-Sp8 |
| Neu5Aca2-3Galb1-4GlcNAcb1-6(Galb1-3)GalNAca-Sp14 | Neu5Gca2-3Galb1-3(Fuca1-4)GlcNAcb-Sp0 |
| Neu5Aca2-3Galb1-4GlcNAcb1-6(Neu5Aca2-3Galb1-3)GalNAca-Sp14 | Neu5Gca2-3Galb1-3GlcNAcb-Sp0 |
| Neu5Aca2-3Galb1-4GlcNAcb1-6(Neu5Aca2-3Galb1-4GlcNAcb1-2)Mana1-6(GlcNAcb1-4)(Neu5Aca2-3Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp21 | Neu5Gca2-3Galb1-4(Fuca1-3)GlcNAcb-Sp0 |
| Neu5Aca2-3Galb1-4GlcNAcb1-6(Neu5Aca2-3Galb1-4GlcNAcb1-2)Mana1-6(GlcNAcb1-4)(Neu5Aca2-3Galb1-4GlcNAcb1-4(Neu5Aca2-3Galb1-4GlcNAcb1-2)Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp21 | Neu5Gca2-3Galb1-4GlcNAcb-Sp0 |
| Neu5Aca2-3Galb1-4GlcNAcb1-6(Neu5Aca2-3Galb1-4GlcNAcb1-3)GalNAca-Sp14 | Neu5Gca2-3Galb1-4Glcb-Sp0 |
| Neu5Aca2-3Galb1-4GlcNAcb1-6GalNAca-Sp14 | Neu5Gca2-6GalNAca-Sp0 |
| Neu5Aca2-3GalNAca-Sp8 | Neu5Gca2-6Galb1-4GlcNAcb-Sp0 |
| Neu5Aca2-3GalNAcb1-4GlcNAcb-Sp0 | Neu5Gcb2-6Galb1-4GlcNAc-Sp8 |
| GalNAcb1-4(Neu5Aca2-3)Galb1-4GlcNAcb-Sp0 | Neu5Gca2-8Neu5Gca2-3Galb1-4GlcNAc-Sp0 |
| GalNAcb1-4(Neu5Aca2-3)Galb1-4GlcNAcb-Sp8 | Neu5Gca2-8Neu5Aca2-3Galb1-4GlcNAc-Sp0 |
| GalNAcb1-4(Neu5Aca2-3)Galb1-4GlcNAcb1-3GalNAca-Sp14 | Neu5Gca2-8Neu5Gca2-3Galb1-4GlcNAcb1-3Galb1-4GlcNAc-Sp0 |
| GlcNAcb1-6(Neu5Aca2-3Galb1-3)GalNAca-Sp14 | Neu5Gca2-8Neu5Gca2-6Galb1-4GlcNAc-Sp0 |
| Fuca1-2Galb1-3GalNAcb1-4(Neu5Aca2-3)Galb1-4Glcb-Sp0 | Neu5,9Ac2a-Sp8 |
| Fuca1-2Galb1-3GalNAcb1-4(Neu5Aca2-3)Galb1-4Glcb-Sp9 | Neu5,9Ac2a2-6Galb1-4GlcNAcb-Sp8 |
| GalNAcb1-4(Neu5Aca2-3)Galb1-4Glcb-Sp0 | Neu5,9Ac2a2-3Galb1-4GlcNAcb-Sp0 |
| Galb1-3GalNAcb1-4(Neu5Aca2-3)Galb1-4Glcb-Sp0 | Neu5,9Ac2a2-3Galb1-3GlcNAcb-Sp0 |
| Neu5Aca2-3Galb1-3GalNAcb1-4(Neu5Aca2-8Neu5Aca2-3)Galb1-4Glcb-Sp0 | |
| Neu5Aca2-6(Neu5Aca2-3)GalNAca-Sp8 | |
| Neu5Aca2-6(Neu5Aca2-3Galb1-3)GalNAca-Sp14 | |
| Neu5Aca2-6(Neu5Aca2-3Galb1-3)GalNAca-Sp8 | Linker structures |
| Neu5Aca2-3Galb1-4GlcNAcb1-2Mana1-6(Neu5Aca2-6Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp12 | Sp0 : -CH2CH2NH2 |
| Neu5Aca2-6Galb1-4GlcNAcb1-2Mana1-6(Neu5Aca2-3Galb1-4GlcNAcb1-2Mana1-3)Manb1-4GlcNAcb1-4GlcNAcb-Sp12 | Sp8 : -CH2CH2CH2NH2 |
| Galb1-4(Fuca1-3)GlcNAcb1-6(Neu5Aca2-6(Neu5Aca2-3Galb1-3)GlcNAcb1-3)Galb1-4Glc-Sp21 | Sp9 : -CH2CH2CH2CH2CH2NH2 |
| Neu5Aca2-6Galb1-4 GlcNAcb1-6(Neu5Aca2-6Galb1-4GlcNAcb1-3)GalNAca-Sp14 | Sp10 : -NHCOCH2NH |
| Neu5Aca2-6Galb-Sp8 | Sp11 : -OCH2C6H4-p-NHCOCH2NH |
| Neu5Aca2-6Galb1-4(6S)GlcNAcb-Sp8 | Sp12 : Asparagine |
| Neu5Aca2-6Galb1-4Glcb-Sp0 | Sp14 : Threonine |
| Neu5Aca2-6Galb1-4Glcb-Sp8 | Sp17 : -OCH2C6H4NH2 |
| Neu5Aca2-6Galb1-4GlcNAcb-Sp0 | Sp19 : EN or NK |
| Neu5Aca2-6Galb1-4GlcNAcb-Sp8 | Sp21 : -N(CH3)-O-(CH2)2-NH2 |
| Neu5Aca2-6Galb1-4GlcNAcb1-2Man-Sp0 | Sp24 : KVANKT |
| Neu5Aca2-6(Galb1-3)GalNAca-Sp14 | |
| Neu5Aca2-6(Galb1-3)GalNAca-Sp8 | |
List of sialylated glycans present on the CFG glycan microarray, representing about 20% of the total number of glycans present.
See the CFG website for more information. Spacer (linker) structures are provided in the table; a- or b- in the structure and prior to the Sp designation indicates the alpha or beta linkage; (6S) indicates sulfate groups and linkage. Yellow highlight indicates the structures that specifically contain Gc sialic acid as opposed to Ac or a derivative.
In addition to mapping the broad recognition of GBPs, the utility of the CFG glycan microarray lies in its versatility for multiple types of comparative binding studies. The arrays can be used to compare sample “sets,” as in wild-type vs. mutant proteins or pathogens. Additionally, assay conditions for the same sample can be compared in order to reveal environmental features of the binding interaction such as calcium dependence. While each array is considered an independent experiment, the “relative” binding feature allows for comparisons to be made, and all of the experiments, scanning, and data analysis are performed in a common location to decrease other variables. The glycans found on the array have been chemo/enzymatically produced, and often structures are replicated with one difference, for example in the terminal sialic acid linkage or even the linker molecule, allowing for fine specificity comparisons of what was once thought erroneously to be “minor” differences. As such, this collection of glycans intrinsically allows for comparative analysis of carbohydrate structural determinants that are important for recognition and binding, and it becomes important to look at what structures are bound as well as related structures that are unbound. For example, examination of the sialic acid recognition of influenza A virus (IAV) hemagglutinin has been completed using the CFG array (Bradley et al., ; Gulati et al., , ; Byrd-Leotis et al., ), and those interactions are exclusively limited to the Neu5Ac form as seen in multiple studies using many IAV strains, with no binding to Neu5Gc (Figure 1), as visualized with the GLycan Array Dashboard (GLAD) analytics program (Mehta and Cummings, ). Interestingly, as swine isolates of IAV were studied on the CFG array, the lack of Neu5Gc binding was maintained, indicating that while such glycans are able to be synthesized within the swine host, they are still unable to be recognized by influenza HA, highlighting the specificity of the receptor binding pocket for the N-acetyl over the N-glycolyl moiety (Bradley et al., ). In broader strokes, the comparative nature of the CFG array has been utilized extensively as a diagnostic indicator of pandemic potential for influenza A viruses as binding preference to terminal sialic acid linkage conformations that are indicative of avian (α2,3-Sia) or human (α2,6-Sia) adaptation are easily visualized (Gulati et al., , ; Byrd-Leotis et al., ). While the synthetic glycan arrays are powerful tools to elucidate the possible recognition by the pathogen or host protein under examination, the biological relevance of such interactions cannot be known. The question is 2-fold: are the glycans that are synthesized in the laboratory representative of those in the host and if so, are they present in enough abundance and localized appropriately in order to be utilized as receptors? In order to study these questions, a different process for generating the glycan microarrays was developed.
Figure 1
Glycans From Natural Sources
Natural glycan microarrays are so designated because the glycans have been directly isolated from host tissues, functionalized, typically partly purified, and then printed on glass slides to create a microarray (Figure 2; Song et al.,
Figure 2

General method for creation and use of glycan microarrays from natural materials.
A more recent study used a human lung shotgun glycan microarray, derived from total human lung glycoproteins, which would not be expected to contain Neu5Gc. Indeed, this was observed, as this glycan microarray helped to identify both sialylated (NeuAc), and phosphorylated oligomannose-type N-glycans recognized by various strains of influenza virus (Byrd-Leotis et al.,
Specialized Sialo-Arrays and Tools
Many groups have generated specialized arrays for the study of specific glycan interactions. Arrays of microbial polysaccharides, which contain sialic acids as well as various derivatives such as 2-keto-3-deoxy-D-glycero-D-galacto-nononic acid (KDN), have been generated to study many types of host-pathogen interactions, for example the examination of human serum antibodies and innate and adaptive immune proteins (Wang et al.,
As mentioned above, many novel sialidases generated by Chen's laboratory were utilized to create sialylated glycan microarrays with interesting modifications to sialic acids including Neu5Gc and 9-O-acetyl derivatives (Yu et al.,
The Neoglycolipid (NGL)-based microarray system uses defined glycans, synthetically or naturally obtained, linked to lipids which are then bound to a nitro-cellulose slide (Palma et al.,
Bifunctional linkers useful for both the detection of HPLC-separated glycan species and direct printing of glycans to NHS slides have been developed (Song et al.,
Limitations of Microarray Approaches
Microarrays have been an incredible tool for investigating binding interactions on a solid surface between the glycans covalently linked to slides and soluble GBPs. However, there are some limitations to the technique. The most straightforward issue is in the number of glycans that are available for addition to the microarrays. There are predicted to be thousands of glycans in the human glycan repertoire (Cummings,
Sialic Acid Binding Reagents
There are a number of reagents that are used in the field for identifying sialic acids. These include using plant or animal lectins, which are naturally occurring glycan-binding proteins, as well as anti-glycan antibodies. On the glycan microarrays, these reagents are detected fluorescently, either due to their direct fluorescence, or with a fluorescently labeled secondary reagent such as streptavidin.
Specifically, Sambucus nigra agglutinin (SNA), Maackia amurensis leukoagglutinin (MAL-I), and Maackia amurensis hemagglutinin (MAH or MAL-II) are all lectins that have been well-characterized in their binding motifs, favoring glycans that contain sialic acid. SNA is a bark lectin from the elderberry plant that has a high affinity toward structures containing terminal Neu5Acα2-6Galβ-. It has unique abilities to differentiate and bind favorably to α2-6-linked sialic acid (Sia)-containing ligands over α2-3-linked sialylated glycans (Cummings and Schnaar,
Commercially available antibodies that are specific in recognizing sialic acid are difficult to find, but the companies Biolegend and Lectenz Bio (www.Lectenz.com) have reagents designated for this purpose. These reagents provide the field with more screening tools for biological samples. Lectenz Bio has a reagent that specifically targets α2-3 linked sialo-glycans over α2-6 and α2-8 linked sialo-glycans, which is similar binding specificity to MAL-I. Another anti-glycan reagent produced by Lectenz Bio aims to broadly identify glycans containing sialic acid in general, independent of the linkage. It remains to be seen whether these reagents can discriminate Ac and Gc. The anti-Neu5Gc antibody from Biolegend is particularly important in studies looking at the effects of the intake and incorporation of Neu5Gc in humans, which has been associated with inflammation and worsening of some diseases (Samraj et al.,
Comparative Analysis of Glycan Microarrays and Data Output
All aspects of glycan microarray technology have advanced significantly from chemical and enzymatic generation of the glycans, to novel release methods, to the development of more efficient functional linkers and immobilization strategies (Gagarinov et al.,
One head-to-head comparison of two similar but novel sialic acid derivative arrays was performed, using the same well-characterized lectins and proteins, and a cross-analysis of the slide images was performed to assess variability (Padler-Karavani et al.,
The MIRAGE efforts were initiated to aid in the cross-comparison of arrays. MIRAGE, or the Minimum Information Required for A Glycomics Experiment, has been setting the standards in the field for performing and reporting on the array methods and data analysis (Kolarich et al.,
Another effort that is paving the way for cross-analyses and centralization of array data is the GlyGen program, https://www.glygen.org. This NIH-funded program is a resource for the glycoscience fields, as a data integration and dissemination tool. Data is retrieved from multiple international sources related to glycan microarrays and other Glycomics data as well as information on the proteins that are tested, and through bioinformatics approaches the data is integrated into a common portal to allow detailed searches and exploration of data. These cross-comparison and integration efforts will allow for validation of data obtained from the myriad of sialic acid-containing glycan microarrays that are currently present in the field.
Concluding Remarks
The platform of glycan microarrays, and specifically arrays containing sialic acid derivatives such as Neu5Ac and Neu5Gc, have greatly accelerated studies of GBPs and their glycan interactors. These efforts will continue to expand and diversify as the significance of glycan recognition for glycoscience in human immunity, cancer therapy, and host-pathogen interactions is better understood and appreciated, and as new tools are introduced to the research community.
Statements
Author contributions
AM, LB-L, JH-M, and RC contributed to the writing of the review manuscript.
Funding
This work was supported by NIH Grant No. P41GM103694 and US Department of Health and Human Services Grant No. HHSN272201400004C.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1
AlymovaI. V.PortnerA.MishinV. P.McCullersJ. A.FreidenP.TaylorG. L. (2012). Receptor-binding specificity of the human parainfluenza virus type 1 hemagglutinin-neuraminidase glycoprotein. Glycobiology22, 174–180. 10.1093/glycob/cwr112
2
AlymovaI. V.YorkI. A.AirG. M.CipolloJ. F.GulatiS.BaranovichT.et al. (2016). Glycosylation changes in the globular head of H3N2 influenza hemagglutinin modulate receptor binding without affecting virus virulence. Sci. Rep.6:36216. 10.1038/srep36216
3
AtackJ. M.DayC. J.PooleJ.BrockmanK. L.BakaletzL. O.BarenkampS. J.et al. (2018). The HMW2 adhesin of non-typeable Haemophilus influenzae is a human-adapted lectin that mediates high-affinity binding to 2-6 linked N-acetylneuraminic acid glycans. Biochem. Biophys. Res. Commun.503, 1103–1107. 10.1016/j.bbrc.2018.06.126
4
BlacklerR. J.EvansD. W.SmithD. F.CummingsR. D.BrooksC. L.BraulkeT.et al. (2016). Single-chain antibody-fragment M6P-1 possesses a mannose 6-phosphate monosaccharide-specific binding pocket that distinguishes N-glycan phosphorylation in a branch-specific mannerdagger. Glycobiology26, 181–192. 10.1093/glycob/cwv093
5
BlixtO.HeadS.MondalaT.ScanlanC.HuflejtM. E.AlvarezR.et al. (2004). Printed covalent glycan array for ligand profiling of diverse glycan binding proteins. Proc. Natl. Acad. Sci. U.S.A.101, 17033–17038. 10.1073/pnas.0407902101
6
BradleyK. C.GallowayS. E.LasanajakY.SongX.Heimburg-MolinaroJ.YuH.et al. (2011b). Analysis of influenza virus hemagglutinin receptor binding mutants with limited receptor recognition properties and conditional replication characteristics. J. Virol.85, 12387–12398. 10.1128/JVI.05570-11
7
BradleyK. C.JonesC. A.TompkinsS. M.TrippR. A.RussellR. J.GramerM. R.et al. (2011a). Comparison of the receptor binding properties of contemporary swine isolates and early human pandemic H1N1 isolates (Novel 2009 H1N1). Virology413, 169–182. 10.1016/j.virol.2011.01.027
8
BriardJ. G.JiangH.MoremenK. W.MacauleyM. S.WuP. (2018). Cell-based glycan arrays for probing glycan-glycan binding protein interactions. Nat. Commun.9:880. 10.1038/s41467-018-03245-5
9
Byrd-LeotisL.JiaN.DuttaS.TrostJ. F.GaoC.CummingsS. F.et al. (2019). Influenza binds phosphorylated glycans from human lung. Sci. Adv.5:eaav2554. 10.1126/sciadv.aav2554
10
Byrd-LeotisL.LiuR.BradleyK. C.LasanajakY.CummingsS. F.SongX.et al. (2014). Shotgun glycomics of pig lung identifies natural endogenous receptors for influenza viruses. Proc. Natl. Acad. Sci. U.S.A.111, E2241–E2250. 10.1073/pnas.1323162111
11
Campanero-RhodesM. A.SmithA.ChaiW.SonninoS.MauriL.ChildsR. A.et al. (2007). N-glycolyl GM1 ganglioside as a receptor for simian virus 40. J. Virol.81, 12846–12858. 10.1128/JVI.01311-07
12
CampbellM. P.AbrahamsJ. L.RappE.StruweW. B.CostelloC. E.NovotnyM.et al. (2019). The minimum information required for a glycomics experiment (MIRAGE) project: LC guidelines. Glycobiology29, 349–354. 10.1093/glycob/cwz009
13
ChenX.KoonerA.S.YuH. (2019). Synthesis of N-glycolylneuraminic acid (Neu5Gc) and its glycoside. Front. Immunol. 10:2004. 10.3389/fimmu.2019.02004
14
ChokhawalaH. A.HuangS.LauK.YuH.ChengJ.ThonV.et al. (2008). Combinatorial chemoenzymatic synthesis and high-throughput screening of sialosides. ACS Chem. Biol.3, 567–576. 10.1021/cb800127n
15
CollinsB. C.GunnR. J.McKitrickT. R.CummingsR. D.CooperM. D.HerrinB. R.et al. (2017). Structural insights into VLR fine specificity for blood group carbohydrates. Structure25, 1667–78. e4. 10.1016/j.str.2017.09.003
16
CummingsR. D. (2009). The repertoire of glycan determinants in the human glycome. Mol. Biosyst.5, 1087–1104. 10.1039/b907931a
17
CummingsR. D.PierceJ. M. (2014). The challenge and promise of glycomics. Chem. Biol.21, 1–15. 10.1016/j.chembiol.2013.12.010
18
CummingsR. D.SchnaarR. L. (2017). R-type lectins, in Essentials of Glycobiology, 3rd Edn, eds VarkiA.CummingsR. D.EskoJ. D.FreezeH. H.StanleyP.BertozziC. R. (Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press), 401–412.
19
DayC. J.PatonA. W.HigginsM. A.ShewellL. K.JenF. E.SchulzB. L.et al. (2017). Structure aided design of a Neu5Gc specific lectin. Sci. Rep.7:1495. 10.1038/s41598-017-01522-9
20
de BoerA. R.HokkeC. H.DeelderA. M.WuhrerM. (2008). Serum antibody screening by surface plasmon resonance using a natural glycan microarray. Glycoconj. J.25, 75–84. 10.1007/s10719-007-9100-x
21
DengL.ChenX.VarkiA. (2013). Exploration of sialic acid diversity and biology using sialoglycan microarrays. Biopolymers99, 650–665. 10.1002/bip.22314
22
DharC.SasmalA.VarkiA. (2019). From “serum sickness” to “xenosialitis”: past, present, and future significance of the non-human sialic acid Neu5Gc. Front. Immunol.10:807. 10.3389/fimmu.2019.00807
23
GagarinovI. A.LiT.TorañoJ. S.CavalT.SrivastavaA. D.KruijtzerJ. A.et al. (2017). Chemoenzymatic approach for the preparation of asymmetric Bi-, Tri-, and Tetra-Antennary N-glycans from a common precursor. J. Am. Chem. Soc.139, 1011–1018. 10.1021/jacs.6b12080
24
GaoC.HanesM. S.Byrd-LeotisL. A.WeiM.JiaN.KardishR. J.et al. (2019). Unique binding specificities of proteins toward isomeric asparagine-linked glycans. Cell Chem Biol26, 535–47.e4. 10.1016/j.chembiol.2019.01.002
25
GildersleeveJ. C.WrightW. S. (2016). Diverse molecular recognition properties of blood group A binding monoclonal antibodies. Glycobiology26, 443–448. 10.1093/glycob/cwv171
26
GulatiS.LasanajakY.SmithD. F.CummingsR. D.AirG. M. (2014). Glycan array analysis of influenza H1N1 binding and release. Cancer Biomark.14, 43–53. 10.3233/CBM-130376
27
GulatiS.SmithD. F.CummingsR. D.CouchR. B.GriesemerS. B.St. GeorgeK.et al. (2013). Human H3N2 influenza viruses isolated from 1968 to 2012 show varying preference for receptor substructures with no apparent consequences for disease or spread. PLoS ONE8:e66325. 10.1371/journal.pone.0066325
28
HamiltonB. S.WilsonJ. D.ShumakovichM. A.FisherA. C.BrooksJ. C.PontesA.et al. (2017). A library of chemically defined human N-glycans synthesized from microbial oligosaccharide precursors. Sci. Rep.7:15907. 10.1038/s41598-017-15891-8
29
Heimburg-MolinaroJ.SongX.SmithD. F.CummingsR. D. (2011). Preparation and analysis of glycan microarrays. Curr. Protoc. Protein Sci. 64, 12.10.1–12.10.29. 10.1002/0471140864.ps1210s64
30
HickeyT. B.ZiltenerH. J.SpeertD. P.StokesR. W. (2010). Mycobacterium tuberculosis employs Cpn60.2 as an adhesin that binds CD43 on the macrophage surface. Cell. Microbiol.12, 1634–1647. 10.1111/j.1462-5822.2010.01496.x
31
HusseinI. T.KrammerF.MaE.EstrinM.ViswanathanK.StebbinsN. W.et al. (2016). New England harbor seal H3N8 influenza virus retains avian-like receptor specificity. Sci. Rep.6:21428. 10.1038/srep21428
32
IelasiF. S.Alioscha-PerezM.DonohueD.ClaesS.SahliH.ScholsD.et al. (2016). Lectin-glycan interaction network-based identification of host receptors of microbial pathogenic adhesins. MBio7:e00584–16. 10.1128/mBio.00584-16
33
JoblingM. G. (2016). The chromosomal nature of LT-II enterotoxins solved: a lambdoid prophage encodes both LT-II and one of two novel pertussis-toxin-like toxin family members in type II enterotoxigenic Escherichia coli. Pathog. Dis.74:ftw001. 10.1093/femspd/ftw001
34
JonesM. B.OswaldD. M.JoshiS.WhiteheartS. W.OrlandoR.CobbB. A. (2016). B-cell-independent sialylation of IgG. Proc. Natl. Acad. Sci. U.S.A.113, 7207–7212. 10.1073/pnas.1523968113
35
KhanZ. M.LiuY.NeuU.GilbertM.EhlersB.FeiziT.et al. (2014). Crystallographic and glycan microarray analysis of human polyomavirus 9 VP1 identifies N-glycolyl neuraminic acid as a receptor candidate. J. Virol.88, 6100–6111. 10.1128/JVI.03455-13
36
KhedriZ.LiY.MuthanaS.MuthanaM. M.HsiaoC. W.YuH.et al. (2014). Chemoenzymatic synthesis of sialosides containing C7-modified sialic acids and their application in sialidase substrate specificity studies. Carbohydr. Res.389, 100–111. 10.1016/j.carres.2014.02.021
37
KolarichD.RappE.StruweW. B.HaslamS. M.ZaiaJ.McBrideR.et al. (2013). The minimum information required for a glycomics experiment (MIRAGE) project: improving the standards for reporting mass-spectrometry-based glycoanalytic data. Mol. Cell. Proteomics12, 991–995. 10.1074/mcp.O112.026492
38
LenmanA.LiaciA. M.LiuY.FrängsmyrL.FrankM.BlaumB. S.et al. (2018). Polysialic acid is a cellular receptor for human adenovirus 52. Proc. Natl. Acad. Sci. U.S.A.115, E4264–73. 10.1073/pnas.1716900115
39
LiW.XiaoA.LiY.YuH.ChenX. (2017). Chemoenzymatic synthesis of Neu5Ac9NAc-containing α2-3- and α2-6-linked sialosides and their use for sialidase substrate specificity studies. Carbohydr. Res.451, 51–58. 10.1016/j.carres.2017.09.003
40
LiangC. H.HsuC. H.WuC. Y. (2015). Sialoside arrays: new synthetic strategies and applications. Top. Curr. Chem.367, 125–149. 10.1007/128_2014_602
41
LinmanM. J.YuH.ChenX.ChengQ. (2012). Surface plasmon resonance imaging analysis of protein binding to a sialoside-based carbohydrate microarray. Methods Mol. Biol.808, 183–194. 10.1007/978-1-61779-373-8_13
42
LiuY.McBrideR.StollM.PalmaA. S.SilvaL.AgravatS.et al. (2017). The minimum information required for a glycomics experiment (MIRAGE) project: improving the standards for reporting glycan microarray-based data. Glycobiology27, 280–284. 10.1093/glycob/cww118
43
MalikS.PetrovaM. I.ImholzN. C.VerhoevenT. L.NoppenS.Van DammeE. J.et al. (2016). High mannose-specific lectin Msl mediates key interactions of the vaginal Lactobacillus plantarum isolate CMPG5300. Sci. Rep.6:37339. 10.1038/srep37339
44
MehtaA. Y.CummingsR. D. (2019). GLAD: GLycan array dashboard, a visual analytics tool for glycan microarrays. Bioinformatics. 10.1093/bioinformatics/btz075 [Epub ahead of print].
45
NoachI.Ficko-BleanE.PluvinageB.StuartC.JenkinsM. L.BrochuD.et al. (2017). Recognition of protein-linked glycans as a determinant of peptidase activity. Proc. Natl. Acad. Sci. U.S.A.114, E679–88. 10.1073/pnas.1615141114
46
Padler-KaravaniV.Hurtado-ZiolaN.PuM.YuH.HuangS.MuthanaS.et al. (2011). Human xeno-autoantibodies against a non-human sialic acid serve as novel serum biomarkers and immunotherapeutics in cancer. Cancer Res.71, 3352–3363. 10.1158/0008-5472.CAN-10-4102
47
Padler-KaravaniV.SongX.YuH.Hurtado-ZiolaN.HuangS.MuthanaS.et al. (2012). Cross-comparison of protein recognition of sialic acid diversity on two novel sialoglycan microarrays. J. Biol. Chem.287, 22593–22608. 10.1074/jbc.M112.359323
48
Padler-KaravaniV.TremouletA. H.YuH.ChenX.BurnsJ. C.VarkiA. (2013). A simple method for assessment of human anti-Neu5Gc antibodies applied to Kawasaki disease. PLoS ONE8:e58443. 10.1371/journal.pone.0058443
49
PalmaA. S.FeiziT.ChildsR. A.ChaiW.LiuY. (2014). The neoglycolipid (NGL)-based oligosaccharide microarray system poised to decipher the meta-glycome. Curr. Opin. Chem. Biol.18, 87–94. 10.1016/j.cbpa.2014.01.007
50
PatwaT.LiC.SimeoneD. M.LubmanD. M. (2010). Glycoprotein analysis using protein microarrays and mass spectrometry. Mass Spectrom. Rev.29, 830–844. 10.1002/mas.20269
51
PetrovaM. I.LievensE.VerhoevenT. L.MacklaimJ. M.GloorG.ScholsD.et al. (2016). The lectin-like protein 1 in Lactobacillus rhamnosus GR-1 mediates tissue-specific adherence to vaginal epithelium and inhibits urogenital pathogens. Sci. Rep.6:37437. 10.1038/srep37437
52
PurohitS.LiT.GuanW.SongX.SongJ.TianY.et al. (2018). Multiplex glycan bead array for high throughput and high content analyses of glycan binding proteins. Nat. Commun.9:258. 10.1038/s41467-017-02747-y
53
SamrajA. N.BertrandK. A.LubenR.KhedriZ.YuH.NguyenD.et al. (2018). Polyclonal human antibodies against glycans bearing red meat-derived non-human sialic acid N-glycolylneuraminic acid are stable, reproducible, complex and vary between individuals: total antibody levels are associated with colorectal cancer risk. PLoS ONE13:e0197464. 10.1371/journal.pone.0197464
54
SamrajA. N.PearceO. M.LäubliH.CrittendenA. N.BergfeldA. K.BandaK.et al. (2017). A red meat-derived glycan promotes inflammation and cancer progression. Proc. Natl. Acad. Sci. U.S.A.112, 542–547. 10.1073/pnas.1417508112
55
SchneiderC.SmithD. F.CummingsR. D.BoliganK. F.HamiltonR. G.BochnerB. S.et al. (2015). The human IgG anti-carbohydrate repertoire exhibits a universal architecture and contains specificity for microbial attachment sites. Sci. Transl. Med.7:269ra1. 10.1126/scitranslmed.3010524
56
SchroederM. N.TribulattiM. V.CarabelliJ.André-LerouxG.CarameloJ. J.CattaneoV.et al. (2016). Characterization of a double-CRD-mutated Gal-8 recombinant protein that retains co-stimulatory activity on antigen-specific T-cell response. Biochem. J.473, 887–898. 10.1042/BJ20150409
57
SmithD. F.CummingsR. D. (2013). Application of microarrays for deciphering the structure and function of the human glycome. Mol. Cell. Proteomics12, 902–912. 10.1074/mcp.R112.027110
58
SongX.Heimburg-MolinaroJ.SmithD. F.CummingsR. D. (2015). Glycan microarrays of fluorescently-tagged natural glycans. Glycoconj. J.32, 465–473. 10.1007/s10719-015-9584-8
59
SongX.JuH.LasanajakY.KudelkaM. R.SmithD. F.CummingsR. D. (2016). Oxidative release of natural glycans for functional glycomics. Nat. Methods13, 528–534. 10.1038/nmeth.3861
60
SongX.JuH.ZhaoC.LasanajakY. (2014). Novel strategy to release and tag N-glycans for functional glycomics. Bioconjug. Chem.25, 1881–1887. 10.1021/bc500366v
61
SongX.LasanajakY.XiaB.Heimburg-MolinaroJ.RheaJ. M.JuH.et al. (2011a). Shotgun glycomics: a microarray strategy for functional glycomics. Nat. Methods8, 85–90. 10.1038/nmeth.1540
62
SongX.XiaB.StowellS. R.LasanajakY.SmithD. F.CummingsR. D. (2009). Novel fluorescent glycan microarray strategy reveals ligands for galectins. Chem. Biol.16, 36–47. 10.1016/j.chembiol.2008.11.004
63
SongX.YuH.ChenX.LasanajakY.TappertM. M.AirG. M.et al. (2011b). A sialylated glycan microarray reveals novel interactions of modified sialic acids with proteins and viruses. J. Biol. Chem.286, 31610–31622. 10.1074/jbc.M111.274217
64
StowellS. R.ArthurC. M.MehtaP.SlaninaK. A.BlixtO.LefflerH.et al. (2008). Galectin-1,-2, and-3 exhibit differential recognition of sialylated glycans and blood group antigens. J. Biol. Chem.283, 10109–10123. 10.1074/jbc.M709545200
65
StruweW. B.AgravatS.Aoki-KinoshitaK. F.CampbellM. P.CostelloC. E.DellA.Set al. (2016). The minimum information required for a glycomics experiment (MIRAGE) project: sample preparation guidelines for reliable reporting of glycomics datasets. Glycobiology26, 907–910. 10.1093/glycob/cww082
66
TemmeJ. S.CampbellC. T.GildersleeveJ. C. (2019). Factors contributing to variability of glycan microarray binding profiles. Faraday Discuss.10.1039/C9FD00021F [Epub ahead of print].
67
VainauskasS.DukeR. M.McFarlandJ.McClungC.RuseC.TaronC. H. (2016). Profiling of core fucosylated N-glycans using a novel bacterial lectin that specifically recognizes alpha1,6 fucosylated chitobiose. Sci. Rep.6:34195. 10.1038/srep34195
68
WangD.LiuS.TrummerB. J.DengC.WangA. (2002). Carbohydrate microarrays for the recognition of cross-reactive molecular markers of microbes and host cells. Nat. Biotechnol.20, 275–281. 10.1038/nbt0302-275
69
WangL.CummingsR. D.SmithD. F.HuflejtM.CampbellC. T.GildersleeveJ. C.et al. (2014). Cross-platform comparison of glycan microarray formats. Glycobiology24, 507–517. 10.1093/glycob/cwu019
70
YamadaK.HirabayashiJ.KakehiK. (2013). Analysis of O-glycans as 9-fluorenylmethyl derivatives and its application to the studies on glycan array. Anal. Chem.85, 3325–3333. 10.1021/ac303771q
71
YorkW. S.AgravatS.Aoki-KinoshitaK. F.McBrideR.CampbellM. P.CostelloC. E.et al. (2014). MIRAGE: the minimum information required for a glycomics experiment. Glycobiology24, 402–406. 10.1093/glycob/cwu018
72
YuH.CaoH.TiwariV. K.LiY.ChenX. (2011). Chemoenzymatic synthesis of C8-modified sialic acids and related α2-3- and α2-6-linked sialosides. Bioorg. Med. Chem. Lett.21, 5037–5040. 10.1016/j.bmcl.2011.04.083
73
YuH.ChokhawalaH.KarpelR.YuH.WuB.ZhangJ.et al. (2005). A multifunctional Pasteurella multocida sialyltransferase: a powerful tool for the synthesis of sialoside libraries. J. Am. Chem. Soc.127, 17618–17619. 10.1021/ja0561690
74
YuH.ChokhawalaH. A.HuangS.ChenX. (2006a). One-pot three-enzyme chemoenzymatic approach to the synthesis of sialosides containing natural and non-natural functionalities. Nat. Protoc.1, 2485–2492. 10.1038/nprot.2006.401
75
YuH.HuangS.ChokhawalaH.SunM.ZhengH.ChenX. (2006b). Highly efficient chemoenzymatic synthesis of naturally occurring and non-natural alpha-2,6-linked sialosides: a P. damsela alpha-2,6-sialyltransferase with extremely flexible donor-substrate specificity. Angew. Chem. Int. Ed. Engl.45, 3938–3944. 10.1002/anie.200600572
Summary
Keywords
sialylated glycans, glycan microarrays, synthetic glycans, natural glycans, glycan binding proteins, functional glycomics, Neu5Ac, Neu5Gc
Citation
McQuillan AM, Byrd-Leotis L, Heimburg-Molinaro J and Cummings RD (2019) Natural and Synthetic Sialylated Glycan Microarrays and Their Applications. Front. Mol. Biosci. 6:88. doi: 10.3389/fmolb.2019.00088
Received
13 March 2019
Accepted
28 August 2019
Published
13 September 2019
Volume
6 - 2019
Edited by
Vered Padler-Karavani, Tel Aviv University, Israel
Reviewed by
Ten Feizi, Imperial College London, United Kingdom; Vincenzo Desiderio, Second University of Naples, Italy
Updates

Check for updates
Copyright
© 2019 McQuillan, Byrd-Leotis, Heimburg-Molinaro and Cummings.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Jamie Heimburg-Molinaro jheimbur@bidmc.harvard.eduRichard D. Cummings rcummin1@bidmc.harvard.edu
This article was submitted to Cellular Biochemistry, a section of the journal Frontiers in Molecular Biosciences
†Co-first authors
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.